ISSN 2305-3127 (Print)   
ISSN 2664-3790 (Online)

 

Клінічний випадок хвороби Фабрі: цікава знахідка в пацієнта кардіохірургічного профілю

О.А. Єпанчінцева, А.С. Солонович, А.В. Бесага, О.Й. Жарінов

Література

  1. Волгина С.Я. Болезнь Фабри. Практическая медицина (научно-практический медицинский журнал). 2012. № 7 (62). С. 75–79.
  2. Горовенко Н.Г., Ліщишина О.М., Дороніна Я.Г. та ін. Хвороба Фабрі: клінічна настанова, заснована на доказах. 2018. 79 с.
  3. Фирсов К.В., Котов А.С. Неврологические проявления при болезни Фабри. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016. № 116 (9). С. 98–105. https://doi.org/10.17116/jnevro20161169198-105
  4. Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, Oder D, Watkinson OT, Bichet DG, Khan A, Iwanochko M, Vaz FM, van Kuilenburg ABP, West ML, Hughes DA, Hollak CEM. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55(5):351–8. doi: 10.1136/jmedgenet-2017-104863.
  5. Azevedo O, Gal A, Faria R, Gaspar P, Miltenberger-Miltenyi G, Gago F, Dias F, Martins A, Rodrigues J, Reimao P, Pereira O, Simoen S, Lopez E, Guimaraes MJ, Sousa N, Cunha D. Founder effect of Fabry disease due to p.F113L mutation: clinical profile of a late-onset phenotype. Mol Genet Metab. 2020;129:150–60.
  6. Barbey F, Qanadli S, Juli C, Brakch N, Palaek T, Rizzo E, Jeanrenaud X, Eckhardt B, Linhart A. Aortic remodelling in Fabry disease. Eur Heart J. 2010;31(3):347–53. https://doi.org/10.1161/CIRCULATIONAHA.114.009789
  7. Barold SS. Arrhythmias: changing indications for biventricular pacing in bradycardia. Nat Rev Cardiol. 2013;10:436–8. doi: 10.1038/nrcardio.2013.88. 
  8. Bénichou B, Goyal S, Sung C, Norfleet AM, O’Brien F. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab. 2009;96:4–12. doi: 10.1016/j.ymgme.2008.10.004.
  9. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013;15:1070–118. doi:10.1093/europace/eut206. Epub 2013 Jun 24.
  10. Brogden G, Shammas H, Maalouf K, Samara LN, Wetzel G, Amiri M, Köckritz-Blickwede M, Das AM, Naim HY. Case study on the pathophysiology of Fabry disease: abnormalities of cellular membranes can be reversed by substrate reduction in vitro. Biosci Rep. 2017;37(2):BSR20160402. doi:10.1042/BSR20160402. PMID: 28351893; PMCID: PMC5408660.
  11. Calcagnino M, O’Mahony C, Coats C, Cardona M, Garcia A, Janagarajan K, Mehta A, Hughes D, Murphy E, Lachmann R. Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson–Fabry disease. J Am Coll Cardiol. 2011;58:88–9.
  12. Chan B, Adam DN. A Review of Fabry Disease. Skin Therapy Lett. 2018;23(2):4–6. PMID: 29562089.
  13. Choi L, Vernon J, Kopach O, Minett MS, Mills K, Clayton PT, Meert T, Wood JN. The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neurosci Lett. 2015;594:163–8. doi:10.1016/j.neulet.2015.01.084. 
  14. De Francesco PN, Mucci JM, Ceci R, Fossati CA, Rozenfeld  PA. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab. 2013;109(1):93–9. doi:10.1016/j.ymgme.2013.02.003.
  15. Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, mor­­phologic, and biochemical studies. Circulation. 1976;54(5):818–25. doi: 10.1161/01.cir.54.5.818. PMID: 824066.
  16. Deva DP, Hanneman K, Li Q, Ng MY, Wasim S, Morel  C, Iwanochko RM, Thavendiranathan P, Crean AM. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease. J Cardiovasc Magn Reson. 2016;18:14. doi: 10.1186/s12968-016-0233-6.
  17. Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017. J Med Genet. 2018;55(4):261–8. doi:10.1136/jmedgenet-2017-105080.
  18. Domm JM, Wootton SK, Medin JA, West ML. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing. Mol Genet Metab. 2021;134(1–2):117–31. doi:10.1016/j.ymgme.2021.07.006.
  19. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopou­­los P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. doi:10.1093/eurheartj/ehu284.
  20. Eng C, Germain D, Banikazemi M, Warnock DG, Wanner C, Hopkin RG, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR. Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2008;8:539–48. https://doi.org/10.1097/01.gim.0000237866.70357.c6.
  21. FDA approves new treatment for a rare genetic disorder, Fabry disease. URL: https://www.fda.gov/news-events/press-announcements/ | FDA.
  22. Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, Shankar S, Nedd K, Olivotto I, Ortiz D, Ohashi T, Hamazaki T, Skuban N, Yu J, Barth JA, Nicholls K. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020;131(1–2):219–28. doi:10.1016/j.ymgme.2020.07.007.
  23. Ferraz MJ, Kallemeijn WW, Mirzaian M, Herrera Moro D, Marques A, Wisse P, Boot RG, Willems LI, Overkleeft HS, Aerts JM. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim Biophys Acta. 2014;1841(5):811–25. doi:10.1016/j.bbalip.2013.11.004.
  24. Ferreira S, Auray-Blais C, Boutin M, Lavoie P, Nunes JP, Martins E, Garman S, Oliveira JP. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. Clin Chim Acta. 2015;447:96–104. doi:10.1016/j.cca.2015.06.003.
  25. Frustaci A, Chimenti C, Doheny D, Desnick RJ. Evolution of cardiac pathology in classic Fabry disease: Progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy. Int J Cardiol. 2017;248:257–62. doi:10.1016/j.ijcard.2017.06.079. Epub 2017 Jun 23. PMID: 28688718.
  26. Frustaci A, Verardo R, Grande C, Galea N, Piselli P, Carbone I, Alfarano M, Russo MA, Chimenti C. Immune-mediated myocarditis in Fabry disease cardiomyopathy. J Am Heart Assoc. 2018;7(17):e009052. doi:10.1161/JAHA.118.009052. PMID: 30371172; PMCID: PMC6201436.
  27. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. doi:10.1186/1750-1172-5-30. PMID: 21092187; PMCID: PMC3009617.
  28. Germain, DP, Fouilhoux A, Decramer S, Tardieu M, Pillet  P, Fila M, Rivera S, Deschênes G, Lacombe D. Consensus re­­commendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin genetics. 2019;96(2):107–17. https://doi.org/10.1111/cge.13546.
  29. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol. 2004;251(5):564–570. doi:10.1007/s00415-004-0364-9. PMID: 15164189.
  30. Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, Ortiz A, Patel MR, Sims K, Waldek S, War-nock DG, Wilcox WR. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. Mol Genet Metab. 2016;119(1–2):151–9. doi:10.1016/j.ymgme.2016.06.007. Epub 2016 Jun 13. PMID: 27510433.
  31. Ikari Y, Kuwako K, Yamaguchi T. Fabry’s disease with complete atrioventricular block: histological evidence of invol­­vement of the conduction system. Br Heart J. 1992;68(3):323–5. doi:10.1136/hrt.68.9.323.
  32. Kaissarian N, Kang J, Shu L, Ferraz MJ, Aerts JM, Shayman JA. Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cells. Mol Genet Metab. 2018;125(4):338–44. doi:10.1016/j.ymgme.2018.10.007. Epub 2018 Nov 2. PMID: 30413389; PMCID: PMC6554739.
  33. Kok K, Zwiers KC, Boot RG, Overkleeft HS, Aerts JMFG, Artola M. Fabry disease: molecular basis, pathophysio­­logy, diagnostics and potential therapeutic directions. Biomolecules. 2021;11(2):271. doi:10.3390/biom11020271. PMID: 33673160; PMCID: PMC7918333.
  34. Kozor R, Grieve SM, Tchan MC, Callaghan F, Hamilton-Craig C, Denaro C, Moon JC, Figtree GA. Cardiac involve­­­­­­ment in genotype-positive Fabry disease patients assessed by cardiovascular MR. Heart. 2016;102(4):298–302. doi:10.1136/heartjnl-2015-308494. Epub 2016 Jan 4. PMID: 26729695.
  35. Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021;81(6):635–45. doi:10.1007/s40265-021-01486-1. Epub 2021 Mar 15. PMID: 33721270; PMCID: PMC8102455.
  36. Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E. Multicenter Female Fabry Study (MFFS) – clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis. 2016;11(1):88. doi:10.1186/s13023-016-0473-4. PMID: 27356758; PMCID: PMC4928260.
  37. Lidove O, Zeller V, Chicheportiche V, Meyssonnier V, Sené T, Godot S, Ziza JM. Musculoskeletal manifestations of Fabry disease: A retrospective study. Joint Bone Spine. 2016;83(4):421–6. doi:10.1016/j.jbspin.2015.11.001. Epub 2015 Dec 14. PMID: 26697993.
  38. Linhart A. The heart in Fabry disease. Perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis, 2006. Chapter 20. PMID: 21290675.
  39. Linhart A, Germain DP, Olivotto, Akhtar MM, Anastasa­­kis A, Hughes D, Namdar M, Pieroni M, Hagège A, Cecchi F, Gimeno JR, Limongelli G, Elliott P. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail. 2020;22(7):1076–96.
  40. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudová J, Karetová D, Zeman J, Ledvinová J, Poupetová H, Elleder M, Aschermann M. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J. 2000;139(6):1101–8. doi:10.1067/mhj.2000.105105. PMID: 10827394.
  41. Loso J, Lund N, Avanesov M, Muschol N, Lezius S, Cordts K, Schwedhelm E, Patten M. Serum biomarkers of endothelial dysfunction in Fabry associated cardiomyopathy. Frontiers in cardiovasc med. 2018;5:108. https://doi.org/10.3389/fcvm.2018.00108
  42. Lücke T, Höppner W, Schmidt E, Illsinger S, Das AM. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab. 2004;82(1):93–7. doi:10.1016/j.ymgme.2004.01.011. PMID: 15110329.
  43. Marek J, Palecek T, Magne J, Lavergne D, Boulogne C, Fadel BM, Jaccard A, Linhart A, Mohty D. Comparison of echocardiographic parameters in Fabry cardiomyopathy and light-chain cardiac amyloidosis. Echocardiography. 2018;35(11):1755–63. doi:10.1111/echo.14144. Epub 2018 Sep 24. PMID: 30247786.
  44. Mauhin W, Benveniste O, Amelin D, Montagner C, Lamari  F, Caillaud C, Douillard C, Dussol B, Leguy-Seguin V, D’Halluin P, Noel E, Zenone T, Matignon M, Maillot F, Ly KH, Besson G, Willems M, Labombarda F, Masseau A, Lavigne C, Lidove O. Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease. PloS one. 2020;15(5):e0233460. https://doi.org/10.1371/journal.pone.0233460
  45. Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, Rolfs A, Rivera A, Waldek S, Germain DP. Fabry disease: a review of current management strategies. QJM. 2010;103(9):641–59. doi:10.1093/qjmed/hcq117. Epub 2010 Jul 21. PMID: 20660166.
  46. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54. doi:10.1001/jama.281.3.249. PMID: 9918480.
  47. Miller JJ, Kanack AJ, Dahms NM. Progress in the understanding and treatment of Fabry disease. Biochim Biophys Acta Gen Subj. 2020;1864(1):129437. doi:10.1016/j.bbagen.2019.129437. Epub 2019 Sep 14. PMID: 31526868; PMCID: PMC6981246.
  48. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta  A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 2003;24(23):2151–5. doi:10.1016/j.ehj.2003.09.017. PMID: 14643276.
  49. Motabar O, Sidransky E, Goldin E, Zheng W. Fabry disease – current treatment and new drug development. Curr Chem Genomics. 2010;23(4):50–6. doi:10.2174/1875397301004010050. PMID: 21127742; PMCID: PMC2995157
  50. Namdar M, Steffel J, Vidovic M, Brunckhorst CB, Holz­­mei­­­ster J, Lüscher TF, Jenni R, Duru F. Electrocardiogra­­phic changes in early recognition of Fabry disease. Heart. 2011;97(6):485–90. doi:10.1136/hrt.2010.211789. Epub 2011 Jan 26. PMID: 21270075.
  51. National Fabry Disease Foundation. https://www.fabrydisease.org/index.php/component/content/article?id=130.
  52. Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F. Differences in Fabry cardiomyopathy bet­­ween female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4(6):592–601. doi:10.1016/j.jcmg.2011.01.020. PMID: 21679893.
  53. Niemann M, Liu D, Hu K, Herrmann S, Breunig F, Strotmann J, Störk S, Voelker W, Ertl G, Wanner C, Weidemann F. Prominent papillary muscles in Fabry disease: a diagnostic marker? Ultrasound Med Biol. 2011;37(1):37–43. doi:10.1016/j.ultrasmedbio.2010.10.017. Epub 2010 Nov 16. PMID: 21084151.
  54. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Got­­­tes­­­man  MM, Brady RO, Kulkarni AB. alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA. 1997;94(6):2540–4. doi:10.1073/pnas.94.6.2540. PMID: 9122231; PMCID: PMC20124.
  55. Oliveira JP, Nowak A, Barbey F, Torres M, Nunes JP, Teixeira-E-Costa F, Carvalho F, Sampaio S, Tavares I, Pereira O, Soares AL, Carmona C, Cardoso MT, Jurca-Simina IE, Spada M, Ferreira S, Germain DP. Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: Natural history in males. Eur J Med Genet. 2020;63(2):103703. doi:10.1016/j.ejmg.2019.103703. Epub 2019 Jun 11. PMID: 31200018.
  56. O’Mahony C, Coats C, Cardona M, Garcia A, Calcag­­­ni-no M, Murphy E, Lachmann R, Mehta A, Hughes D, Elliott PM. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace. 2011;13(12):1781–8. doi:10.1093/europace/eur267. Epub 2011 Aug 18. PMID: 21856674.
  57. Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, Ramaswami U, Parini R, Sunder-Plassman G, Beck M, Mehta AB; FOS Investigators. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol. 2007;157(2):331–7. doi:10.1111/j.1365-2133.2007.08002.x. Epub 2007 Jun 15. PMID: 17573884.
  58. Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, Warnock DG. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant. 2010;25(3):769–75. doi:10.1093/ndt/gfp554. Epub 2009 Oct 21. PMID: 19846394.
  59. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer  M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416–27. doi:10.1016/j.ymgme.2018.02.014. Epub 2018 Feb 28. PMID: 29530533.
  60. Palecek T, Dostalova G, Kuchynka P, Karetova D, Bultas  J, Elleder  M, Linhart A. Right ventricular involvement in Fabry disease. J Am Soc Echocardiogr. 2008;21(11):1265–8. doi:10.1016/j.echo.2008.09.002. Epub 2008 Oct 4. PMID: 18835697.
  61. Patel V, O’Mahony C, Hughes D, Rahman MS, Coats C, Murphy  E, Lachmann R, Mehta A, Elliott PM. Clinical and genetic predictors of major cardiac events in patients with Anderson–Fabry Disease. Heart. 2015;101(12):961–6. doi:10.1136/heartjnl-2014-306782. Epub 2015 Feb 5. PMID: 25655062.
  62. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42. doi:10.1161/CIRCULATIONAHA.114.013255. Epub 2014 Nov 18. PMID: 25406305.
  63. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81. doi:10.1093/eurheartj/ehw106. Epub 2016 May 23. PMID: 27222591; PMCID: PMC4986030.
  64. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ; ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867. doi: 10.1093/eurheartj/ehv316. Epub 2015 Aug 29. PMID: 26320108.
  65. Regenbogen C, Braunisch MC, Schmaderer C, Heemann U. Fabry disease: what the cardiologist should consider in non-cardiac screening, diagnosis, and management-narrative review. Cardiovasc Diagn Ther. 2021;11(2):661–71. doi:10.21037/cdt-20-845. PMID: 33968643; PMCID: PMC8102250.
  66. Reuser AJ, Verheijen FW, Bali D, van Diggelen OP, Germain DP, Hwu WL, Lukacs Z, Mühl A, Olivova P, Piraud M, Wuyts B, Zhang K, Keutzer J. The use of dried blood spot samples in the diagnosis of lysosomal storage disorders-current status and perspectives. Mol Genet Metab. 2011;104(1–2):144–8. doi:10.1016/j.ymgme.2011.07.014. Epub 2011 Jul 23. PMID: 21831684.
  67. Rogers DP, Marazia S, Chow AW, Lambiase PD, Lowe MD, Frenneaux M, McKenna WJ, Elliott PM. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. Eur J Heart Fail. 2008;10(5):507–13. doi:10.1016/j.ejheart.2008.03.006. Epub 2008 Apr 10. PMID: 18406204.
  68. Rozenfeld P, Neumann PM. Treatment of fabry disease: current and emerging strategies. Curr Pharm Biotechnol. 2011;12(6):916–22. doi:10.2174/138920111795542705. PMID: 21235448.
  69. Satoh K. Globotriaosylceramide induces endothelial dysfunction in Fabry disease. Arteriosclerosis, Thrombosis, and Vascular Biol. 2014;34:2–4. https://doi.org/10.1161/ATVBAHA.113.
  70. Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, Mehta AB, Elliott PM. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 2005;96(6):842–6. doi:10.1016/j.amjcard.2005.05.033. PMID: 16169374.
  71. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, Kaneski CR. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008;95(3):163–8. doi:10.1016/j.ymgme.2008.06.016. Epub 2008 Aug 15. PMID: 18707907; PMCID: PMC2593623.
  72. Silva CAB, Moura-Neto JA, Dos Reis MA, Vieira Neto OM, Barreto FC. Renal manifestations of Fabry disease: A Narrative Review. Can J Kidney Health Dis. 2021;8:2054358120985627. doi:10.1177/2054358120985 627. PMID: 33786192; PMCID: PMC7960898.
  73. Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, Timmermans J, Weidemann F, West  ML, Biegstraaten M, Lekanne Deprez RH, Florquin S, Postema PG, Tomberli B, van der Wal AC, van den Bergh Weerman MA, Hollak CE. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol. 2014;177(2):400–8. doi:10.1016/j.ijcard.2014.09.001. Epub 2014 Sep 20. PMID: 25442977.
  74. Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Nino-miya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Yoshimitsu M, Higuchi K, Nakao S, Anan R, Minagoe S, Tei C. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008;51(1):50–9. doi:10.1016/j.jjcc.2007.12.001. Epub 2008 Feb 6. PMID: 18522775.
  75. Van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, Hollak CE. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1–9. doi:10.1136/jmedgenet-2013-101857. Epub 2013 Aug 6. PMID: 23922385.
  76. Van der Veen SJ, Hollak CEM, van Kuilenburg ABP, Lange­­veld M. Developments in the treatment of Fabry disease. J Inherit Metab Dis. 2020;43(5):908–21. doi:10.1002/jimd.12228. Epub 2020 Mar 2. PMID: 32083331; PMCID: PMC7540041.
  77. Weidemann F, Niemann M, Störk S, Breunig F, Beer M, Sommer C, Herrmann S, Ertl G, Wanner C. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274(4):331–41. doi:10.1111/joim.12077. Epub 2013 May 6. PMID: 23586858; PMCID: PMC4282332.
  78. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP; Fabry Registry. Fema­­les with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93(2):112–28. doi:10.1016/j.ymgme.2007.09.013. Epub 2007 Nov 26. PMID: 18037317.
  79. Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banika­­zemi M, Packman S, Sims K, Solomon SD. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J. 2010;31(9):1088–97. doi:10.1093/eurheartj/ehp588. Epub 2010 Jan 7. PMID: 20061327; PMCID: PMC2912636
  80. Yogasundaram H, Hung W, Paterson ID, Sergi C, Oudit GY. Chloroquine-induced cardiomyopathy: a reversible cause of heart failure. ESC Heart Fail. 2018;5(3):372–5. doi:10.1002/ehf2.12276. Epub 2018 Feb 20. PMID: 29460476; PMCID: PMC5933951.
  81. Zemánek D, Marek J, Dostálová G, Magage S, Roblová L, Kovárník T, Linhart A. Usefulness of alcohol septal ablation in the left ventricular outflow tract obstruction in Fabry disease cardiomyopathy. Am J Cardiol. 2021;150:110–3. doi:10.1016/j.amjcard.2021.03.042. Epub 2021 May 16. PMID: 34011439.
[PDF] [Зміст журналу]  

 

Crossref Member Badge

Анонс

ФУНКЦІОНАЛЬНА ДІАГНОСТИКА СЕРЦЕВО-СУДИННИХ ХВОРОБ

ХII щорічна науково-практична конференція
14–15 березня 2024 року

ПРОГРАМА КОНФЕРЕНЦІЇ

____________________________

 

Партнери сайту

Berlin-Chemie Menarini

Цибор